Cargando…
Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
Nitazoxanide is a Food and Drug Administration-approved antiprotozoal drug recently demonstrated to be selectively active against quiescent and glucose-deprived tumour cells. This drug also has several characteristics that suggest its potential as a radiosensitizer. The present study aimed to invest...
Autores principales: | Karlsson, Henning, Fryknäs, Mårten, Senkowski, Wojciech, Larsson, Rolf, Nygren, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867181/ https://www.ncbi.nlm.nih.gov/pubmed/35261637 http://dx.doi.org/10.3892/ol.2022.13243 |
Ejemplares similares
-
A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation
por: Karlsson, Henning, et al.
Publicado: (2019) -
Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
por: Ek, Frida, et al.
Publicado: (2022) -
Iron chelators target both proliferating and quiescent cancer cells
por: Fryknäs, Mårten, et al.
Publicado: (2016) -
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
por: Nygren, Peter, et al.
Publicado: (2013) -
Descriptive Proteome Analysis to Investigate Context-Dependent
Treatment Responses to OXPHOS Inhibition in Colon Carcinoma Cells
Grown as Monolayer and Multicellular Tumor Spheroids
por: Steinmetz, Julia, et al.
Publicado: (2020)